COBI-AVM Study - Phase 2 Study to Assess the Safety and Efficacy of Cobimetinib In Extracranial Arteriovenous Malformations (AVM)
Latest Information Update: 22 Jul 2024
At a glance
- Drugs Cobimetinib (Primary)
- Indications Arteriovenous malformations
- Focus Therapeutic Use
- Acronyms COBI-AVM Study
- 23 Jan 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2026.
- 23 Jan 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2026.
- 06 Jul 2022 Planned initiation date changed from 1 Jun 2022 to 1 Jul 2022.